Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience

Ganguly, Siddhartha; Uvodich, Mason E.; Dias, Ajoy; McGuirk, Joseph P.

doi:10.1016/j.lrr.2018.06.002

Cited by 3 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most cases, it occurs in myelodysplastic/myeloproliferative neoplasms (MDS/MPN), high-risk myelodysplastic syndrome, or acute myeloid leukemia (AML). It leads to distinctive morphologic characteristics such as pseudo-Pelger-Huet neutrophils and megakaryocytes of small hypolobated morphology [ 10 , 28 ]. In a majority of cases, the clinical course of myeloid neoplasms with isolated i(17q) is aggressive regardless of diagnosis or blast count.…”

Section: Introductionmentioning

confidence: 99%

“…According to the revised International Prognostic Scoring System (IPSS), the presence of isochromosome (17q) is classified as an “intermediate prognostic factor” for MDS, and as listed in the revised Medical Research Council classification, it is considered as an adverse prognostic factor for AML, which determines the use of more aggressive forms of therapy, including stem cell transplantation [ 8 , 10 , 27 ]. Numerous studies confirmed that i(17q) can be a prognostic marker of disease progression and shortened overall survival [ 28 ]. However, other studies report on the considerable heterogeneity of the clinical course of myeloid neoplasms with i(17q) [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

“…Numerous studies confirmed that i(17q) can be a prognostic marker of disease progression and shortened overall survival [ 28 ]. However, other studies report on the considerable heterogeneity of the clinical course of myeloid neoplasms with i(17q) [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

“…To assess clinical features and disease outcome, Ganguly et al [ 28 ] examined patients with myeloid neoplasms and the presence of i(17q) as single or complex change. They identified 14 patients, 12 with complex and 2 with a single abnormality.…”

Section: Introductionmentioning

confidence: 99%

“…Of note, an increased OS was observed in the subjects who underwent hematopoietic stem cell transplantation (HSCT) in comparison to those who were on conventional chemotherapy. The authors concluded that the role of HSCT in patients with i(17q) needs further study and a larger platform of data from transplantation centers [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic significance of isochromosome 17q in hematologic malignancies

et al. 2021

View full text Add to dashboard Cite

Isochromosome 17q [i(17q)] with its two identical long arms is formed by duplication of the q arm and loss of the short p arm. The breakpoint in chromosome 17 that allows the formation of this isochromosome is located at 17p11.2, and the ~240 kb region with its large, palindromic, low-copy repeat sequences are present here. The region is highly unstable and susceptible to a variety of genomic alterations which may be induced by or without toxic agents. One molecular consequence of i(17q) development is the obligatory loss of a single TP53 allele of the tumor suppressor P53 protein located at 17p13.1. Isochromosome 17q is involved in cancer development and progression. It occurs in combination with other chromosomal defects (complex cytogenetics), and rarely as a single mutation. The i(17q) rearrangement has been described as the most common chromosomal aberration in primitive neuroectodermal tumors and medulloblastomas. This isochromosome is also detected in different hematological disorders. In this article, we analyze literature data on the presence of i(17q) in proliferative disorders of the hematopoietic system in the context of its role as a prognostic factor of disease progression. The case reports are added to support the presented data. Currently, there are no indications for the use of specific treatment regimens in the subjects with a presence of the isochromosome 17q. Thus, it is of importance to continue studies on the prognostic role of this abnormality and even single cases should be reported as they may be used for further statistical analyses or meta-analyses.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic significance of isochromosome 17q in hematologic malignancies

et al. 2021

View full text Add to dashboard Cite

show abstract

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis

Küçükyurt

Kelezoğlu

Elverdi

et al. 2023

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

2021

View full text Add to dashboard Cite

The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms. The group consists of chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia, BCR-ABL1-negative (aCML), juvenile myelomonocytic leukemia (JMML), myelodysplastic/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis (MDS/MPN-RS-T), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). The most frequent entity in this category is CMML, while all other diseases are extremely rare. Thus, only very limited data on the epidemiology of these subgroups exists. An appropriate diagnosis and classification can be challenging since the diagnosis is still largely based on morphologic criteria and myelodysplastic as well as myeloproliferative features can be found in various occurrences. The diseases in this category share several features that are common in this specific WHO-category, but also exhibit specific traits for each disease. This review summarizes published data on epidemiological features and offers a brief overview of the main diagnostic criteria and clinical characteristics of the five MDS/MPN subgroups.

show abstract

Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience

Cited by 3 publications

References 6 publications

Prognostic significance of isochromosome 17q in hematologic malignancies

Prognostic significance of isochromosome 17q in hematologic malignancies

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

Contact Info

Product

Resources

About